Novel C-ring analogues of 20(S)-camptothecin-part-2: Synthesis and in vitro cytotoxicity of 5-C-substituted 20(S)-camptothecin analogues

Bioorganic and Medicinal Chemistry Letters

Volumn 9, Issue 12, 1999, Pages 1633-1638

  Subrahmanyam, Duvvuri ^a   Venkateswarlu, Akella ^a   Rao, Kalla Venkateswara ^a   Sastry, Tungathurty VRS ^a   Vandana, Garikipati ^b   Kumar, Sadhukhan A ^b  

^a Natural Products Division   (India)

^b DR REDDY S RESEARCH FOUNDATION   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN DERIVATIVE; IRINOTECAN; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CYTOTOXICITY; DRUG ACTIVITY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0033591764     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(99)00268-1     Document Type: Article

References (31)

1. (a) Wall, M.E.; Wani, M.C.; Cook, C.E.; Palmer, K.H.; McPhail, A.T.; Sim, G.A., J.Am.Chem.Soc., 1966, 88, 3888-3890;
2. (b) Govindachari, T.R.; Viswanadhan, N.; Indian J.Chem., 1972, 10, 453;
3. (a) Gottlieb, J.A.; Guarino, A.M.; Call, J.B.; Olivero, V,T.; Block, J,B.; Cancer Chemother. Rep. 1970, 54, 461-470.
4. (b) Muggia, F.M.; Creaven, P.J.; Hansen, H.H.; Cohen, M.H..; Selawry, O. S., Biochemistry, 1972, 56, 515-521.
5. (a) Cao, Z.; Harris, N.; Kozielski, A; Vardeman, D.; Stehlin, J.S.; Giovanella, B., J.Med.Chem., 1998, 41, 31-37;
6. (b) Josien, H.; Bom, D.; Curran, D.P.; Zheng, Y-H.; Chan, T-C., Bioorg. Med. Chem.Lett., 1997, 24, 3189-3194;
7. (c) Lavergne, O.; Lesueur-Ginot, L.; Pla Rodas, F.; Bigg, D.C.H., Bioorg.Med.Chem.Lett., 1997, 7, 2235-2238;
8. (d) A review : Sawada, S.; Yokokura, T.; Miyasaka, T., Curr. Pharm.Des., 1995, 1, 113-132;
9. (e) Wall, M.E.; Wani, M.C.; Nicholas, A.W.; Manikumar, G.; Tele, C.; Moore, L.; Truesdale, A.; Leitner, P.; Besterman, J.M., J. Med. Chem., 1993, 36, 2689-2700.
10. (a) Kingsbury, W.D.; Boehm, C.J.; Jakas, D.R.; Holden, K.G.; Hecht, S.M.; Gallagher, G.; Caraufa, M.J.; McCaabe, F.L.; Faucette, L.F.; Johnson, R.K.; Hertzberg, R.P., J.Med.Chem., 1991, 34, 98-107;
11. (b) Drugs of Future, 1995, 20 (5), 483-489.
12. Sawada, S.; Okajima, S,; Aiyama. R.; Nakata, K.; Furuta, T.; Yokokura, T.; Sugino, E.; Yamaguchi, K.; Miyasaka, T., Chem.Pharm.Bull., 1991, 39, 1446-1454.
13. (a)9-Amino Camptothecin: Robinson, C.; Robinson, K.; Castaner, J.; Drugs of Future, 1996, 21, 881-889;
14. (b) GG 211; Luzzio, M.J.; Besterman, J.M.; Emerson, D.L.; Evans, M.G.; Lackey, K.; Leitener, P.; McIntyre, G.; Morton, B.; Meyers, P.L.; Peel, M.R.; Sisco, J.M.; Sternbach, D.D.; Tong, W-Q.; Truesdale, A.; Uehling, D.E.; Vuang, A.; Yates, J.; J.Med.Chem., 1995, 38, 395-401;
15. (c) DX 8951: Mitsui, I.; Kumazawa, E.; Hirata, Y.; Aonuma, M.; Sugimori, M.; Ohsuki, S.; Uoto, K.; Ejima, A.; Terasawa, H.; Sato, K.; Jpn. J.Cancer Res., 1995, 86, 776-782.
16. (a) Sawada, S.; Nakata, K.; Furuta, T.; Yokukura, T.; Miyasaka, T., Chem. Pharm. Bull., 1991, 39, 2574-2580;
17. (b) Wang-H-K.; Liu, S-Y.; Hwang, K-M.; McPhail, A.T.; Lee, K- H., Bioorg.Med. Chem. Lett., 1995, 5, 77-82;
18. (c) Fukuda, M., Biochem. Pharmacology, 1985, 34, 1225-1230;
19. (d) Wall, M.E.; Wani, M.C., Economic & Medicinal Plant Research., Academic Press Ltd., 1991, 5, 111-127;
20. (e) Hertzberg, R.P.; Caranfa, M.J.; Holden, K.G.; Jakas, D.R.; Gallagher, G.; Mattern, M.R.; Mong, S-M.; Bartus, J.L.; Johnson, R.K.; Kingsbury, W.D., J.Med.Chem., 1989, 32, 715-720;
21. (f) Sawada, S.; Yaegashi, T.; Furuta, T.; Yokokura, T.; Miyasaka, T.; Chem. Pharm.Bull., 1993, 41, 310- 313;
22. (g) Yaegashi, T.; Sawada, S.; Nagata, H.; Furuta, T.; Yokukura, T.; Miyasaka, T.; Chem. Pharm.Bull., 1994, 42, 2518-2525.
23. For our other contributions in this programme, please see: (a) Novel D-ring analogues of podophyllotoxin as anti-cancer agents, D. Subrahmanyam et.al., Bioorg. Med. Chem. Lett., 1998, 8, 1391-1396;
24. (b) Novel Taxane Derivatives from 14-β-hydroxy-10-deacetylbaccatin III, D. Subrahmanyam et.al., US 5, 763, 477.
25. (a)Part 1 : In vitro cytotoxicity of 5-Aminosubstituted 20(S)-Camptothecins., D. Subrahmanyam et.al., Bioorg. Med. Chem., submitted for publication.;
26. (b) Novel C-ring Analogues of 20(S)-camptothecin-Part-3: 5-substitutedalkoxy Analogues., D. SubrahmaNayam et.al., manuscript in preparation;
27. (c) Novel C-ring Analogues of 20(S)-camptothecin -Part- 4: Synthesis and their in Vitro Cytotoxicity of A-,B- and C-ring Analogues., D. Subrahmanyam et.al., manuscript in preparation.
28. +), 416, 388, 360,316, 191,98.
29. All the C-5-C-substituted compounds submitted for in vitro anti-cancer activity represent a mixture of two diastereomers 20(S),5(S) and 20(S),5(R) app. in the ratio of 1:1(HPLC).
30. (a)Boyd, M.R.; Paull, K.D., Drug.Dev. Res. 1995, 34, 91-109;
31. (b) Paull, K.D.; Shoemaker, R.H.; Hodes, L.; Monks, A.; Scudiero, D.A.; Rubinstein, L.; Plowman, J.; Boyd, M.R., J Natl. Cancer.Inst. 1989, 81, 1088-1092.